Literature DB >> 16005378

Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil.

N Caretta1, P Palego, A Ferlin, A Garolla, A Bettella, R Selice, C Foresta.   

Abstract

OBJECTIVE: To evaluate the possible improvement of sexual activity following a non on-demand administration of a long half-life selective inhibitor of phosphodiesterase type 5 (PDE-5) in elderly patients without major cardiovascular risk factors.
METHODS: Sixty subjects with erectile dysfunction (ED) aged 60-70 years and 30 control patients aged 18-40 years, affected by psychogenic ED, were studied. All underwent routine and hormonal blood tests, Nocturnal Penile Tumescence Rigidity Monitoring test (NPTRM), ultrasonographyc evaluation of common carotid artery intima-media thickness (IMT) and penile colour Doppler ultrasonography (P-CDU). All patients underwent therapy with tadalafil 20 mg in alternative days, non on-demand, at 5.00 p.m., for three consecutive months. IIEF-5, NPTRM test and P-CDU were re-evaluated one month after the end of the therapy.
RESULTS: Among elderly subjects 20 (33%) had normal carotid IMT (< 0.9 mm), 15 (25%) minimal increase of carotid thickness (IMT = 0.9-1.2 mm) and 25 (42%) one or more carotid plaques (IMT > 1.3 mm). NPTRM and P-CDU parameters were inversely related to different degrees of carotid wall alteration and showed a significant improvement respect to pre-treatment only in patients without atherosclerotic plaques. Also IIEF-5 showed significant improvements only in patients without atherosclerotic plaques.
CONCLUSIONS: In elderly subjects with slight or no signs of vascular disease at the carotid level, chronic and non on-demand treatment with tadalafil can induce spontaneous resumption of erections, probably through the improvement of endothelial function, but direct evidences to confirm this hypothesis are required.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005378     DOI: 10.1016/j.eururo.2005.01.013

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  Brachial artery flow-mediated dilatation and carotid intima-media thickness in young ED patients with insulin resistance.

Authors:  S-F Chen; F-J Yao; X-Z Sun; R-P Wu; Y-P Huang; F-F Zheng; Q-Y Yang; D-Y Han; M-Q Xie; M Ding; Y Zhang; G-H Liu; C-H Deng
Journal:  Int J Impot Res       Date:  2016-08-04       Impact factor: 2.896

Review 2.  Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.

Authors:  Frank Sommer; Wolfgang Schulze
Journal:  World J Urol       Date:  2005-11-05       Impact factor: 4.226

Review 3.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

4.  Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?

Authors:  Antonio Aversa; Roberto Bruzziches; Davide Francomano; Marco Natali; Andrea Lenzi
Journal:  Ther Adv Urol       Date:  2009-10

5.  Optimizing postoperative sexual function after radical prostatectomy.

Authors:  Manuela Tutolo; Alberto Briganti; Nazareno Suardi; Andrea Gallina; Firas Abdollah; Umberto Capitanio; Marco Bianchi; Niccolò Passoni; Alessandro Nini; Nicola Fossati; Patrizio Rigatti; Francesco Montorsi
Journal:  Ther Adv Urol       Date:  2012-12

6.  Impact of phosphodiesterase type 5 inhibitors on endothelial function.

Authors:  Patrick E Teloken; John P Mulhall
Journal:  Rev Urol       Date:  2008

7.  Metabolic syndrome and erectile dysfunction: the ultrasound evaluation of cavernosal atherosclerosis.

Authors:  Mirko Schipilliti; Nicola Caretta; Pierfrancesco Palego; Riccardo Selice; Alberto Ferlin; Carlo Foresta
Journal:  Diabetes Care       Date:  2011-07-05       Impact factor: 19.112

8.  Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors.

Authors:  Luca De Toni; Maurizio De Rocco Ponce; Erica Franceschinis; Stefano Dall'Acqua; Roberto Padrini; Nicola Realdon; Andrea Garolla; Carlo Foresta
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

9.  Analysis of cardiovascular risks for erectile dysfunction in Chinese patients with type 2 diabetes mellitus lacking clinical symptoms of cardiovascular diseases.

Authors:  Penghui Yuan; Delin Ma; Yucong Zhang; Xintao Gao; Jiaxin Wang; Rui Li; Zhuo Liu; Tao Wang; Yan Yang; Gang Yuan; Xuefeng Yu; Shaogang Wang; Jihong Liu; Xiaming Liu
Journal:  Transl Androl Urol       Date:  2020-12

Review 10.  Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.

Authors:  Giovanni Vanni Frajese; Flavio Pozzi; Gaetano Frajese
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.